Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Alto Neuroscience, Inc.

Get SEC filing alerts via email and in your feed for Alto Neuroscience, Inc.

ANRO

Alto Neuroscience, Inc.

About Alto Neuroscience, Inc.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on precision psychiatry. It develops personalized treatments for neuropsychiatric disorders such as major depressive disorder, bipolar depression, and schizophrenia using its proprietary Precision Psychiatry Platform. The platform integrates neurobiological data and machine learning to identify biomarkers for targeted patient populations. Alto’s pipeline includes novel small molecules and repurposed drugs designed to improve treatment efficacy and patient outcomes in CNS disorders.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Alto Neuroscience, Inc.

1
1
Alto Neuroscience, Inc. Alto Neuroscience Reports $26.2 Million Net Loss in Q1 2026 Amid Increased R&D Spending

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Alto Neuroscience, Inc. Alto Neuroscience Reports Fiscal Year 2025 Financial Results and Business Developments

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Alto Neuroscience, Inc. Alto Neuroscience Reports $14.2 Million Net Loss in Q3 2025, Cash Reserves Decline

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Alto Neuroscience, Inc. Alto Neuroscience Reports $17.7 Million Net Loss in Q2 2025, Increases Investment in Clinical Development

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Alto Neuroscience, Inc. Alto Neuroscience Reports $15.2 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Alto Neuroscience, Inc. Alto Neuroscience Reports $61.4 Million Net Loss for 2024, Highlights IPO and Clinical Developments

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Alto Neuroscience, Inc. Alto Neuroscience Reports Significant Financial Growth, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments